Hysteroscopic Subchorionic Injection of Methotrexate Followed by Laparoscopic Excision of the Gestational Sac for the Management of Cesarean Scar Ectopic Pregnancy: An Innovative Dual Approach of a Challenging Pathology.
This innovative two-step therapeutic approach should be considered a compelling option for managing cesarean scar ectopic pregnancy. (Source: Fertility and Sterility)
Source: Fertility and Sterility - April 16, 2024 Category: Reproduction Medicine Authors: Maria del Milagro Tejerizo Fe, Paola Elizabeth Benitez, Alejandro Martin Gonzalez, Kyara Marquez, Joelle Mouhanna, Jose Carugno Tags: Video Source Type: research
Decreased serpin C1 in extracellular vesicles predicts response to methotrexate treatment in patients with pulmonary sarcoidosis
Sarcoidosis is a systemic granulomatous disease of unknown etiology primarily affecting the lungs. Treatment is needed when disease symptoms worsen and organ function deteriorates. In pulmonary sarcoidosis, pr... (Source: Respiratory Research)
Source: Respiratory Research - April 16, 2024 Category: Respiratory Medicine Authors: Raisa Kraaijvanger, Montse Janssen Bon ás, Jan C. Grutters, Ioanna Paspali, Marcel Veltkamp, Dominique P. V. de Kleijn and Coline H. M. van Moorsel Tags: Research Source Type: research
Rheumatology: What You May Have Missed in 2023
Ann Intern Med. 2024 Apr 16. doi: 10.7326/M24-0678. Online ahead of print.ABSTRACTMany patients with rheumatologic conditions receive care from physicians other than rheumatologists. Here we note key findings from 6 studies in rheumatology published in 2023 that offer valuable insights for internal medicine specialists and subspecialists outside of rheumatology. The first study investigated the effect of low-dose glucocorticoids on patients with rheumatoid arthritis (RA) over 2 years and challenged existing perceptions about the risks of glucocorticoids in this setting. The second study focused on the updated guideline for...
Source: Annals of Internal Medicine - April 15, 2024 Category: Internal Medicine Authors: Kafaf Jalali Lisa A Mandl Source Type: research
Rheumatology: What You May Have Missed in 2023
Ann Intern Med. 2024 Apr 16. doi: 10.7326/M24-0678. Online ahead of print.ABSTRACTMany patients with rheumatologic conditions receive care from physicians other than rheumatologists. Here we note key findings from 6 studies in rheumatology published in 2023 that offer valuable insights for internal medicine specialists and subspecialists outside of rheumatology. The first study investigated the effect of low-dose glucocorticoids on patients with rheumatoid arthritis (RA) over 2 years and challenged existing perceptions about the risks of glucocorticoids in this setting. The second study focused on the updated guideline for...
Source: Annals of Internal Medicine - April 15, 2024 Category: Internal Medicine Authors: Kafaf Jalali Lisa A Mandl Source Type: research
Rheumatology: What You May Have Missed in 2023
Ann Intern Med. 2024 Apr 16. doi: 10.7326/M24-0678. Online ahead of print.ABSTRACTMany patients with rheumatologic conditions receive care from physicians other than rheumatologists. Here we note key findings from 6 studies in rheumatology published in 2023 that offer valuable insights for internal medicine specialists and subspecialists outside of rheumatology. The first study investigated the effect of low-dose glucocorticoids on patients with rheumatoid arthritis (RA) over 2 years and challenged existing perceptions about the risks of glucocorticoids in this setting. The second study focused on the updated guideline for...
Source: Annals of Internal Medicine - April 15, 2024 Category: Internal Medicine Authors: Kafaf Jalali Lisa A Mandl Source Type: research
Rheumatology: What You May Have Missed in 2023
Ann Intern Med. 2024 Apr 16. doi: 10.7326/M24-0678. Online ahead of print.ABSTRACTMany patients with rheumatologic conditions receive care from physicians other than rheumatologists. Here we note key findings from 6 studies in rheumatology published in 2023 that offer valuable insights for internal medicine specialists and subspecialists outside of rheumatology. The first study investigated the effect of low-dose glucocorticoids on patients with rheumatoid arthritis (RA) over 2 years and challenged existing perceptions about the risks of glucocorticoids in this setting. The second study focused on the updated guideline for...
Source: Annals of Internal Medicine - April 15, 2024 Category: Internal Medicine Authors: Kafaf Jalali Lisa A Mandl Source Type: research
Evaluating the docetaxel effect in an animal model of polyarthritis
ConclusionDTX reduces the progression and joint destruction in rats induced by Complete Freund ’s Adjuvant which may due to inhibition of PAD4, TNF-α, IL-1β, VEGF, and ACPA. Also, methotrexate exhibited anti PAD4 effect. (Source: Inflammopharmacology)
Source: Inflammopharmacology - April 15, 2024 Category: Drugs & Pharmacology Source Type: research
Frontline combination of dasatinib and low-intensity chemotherapy in adults with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia
CONCLUSIONS: Our results suggest that dasatinib-based low-intensity chemotherapy is safe and effective as an induction strategy in the Chinese population. Allo-HSCT plays a crucial role in the long-term outcomes of patients with Ph+ ALL.CLINICAL TRIAL REGISTRATION: The trial was registered at ClinicalTrials.gov as NCT02690922.PMID:38616308 | DOI:10.1080/17474086.2024.2343885 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - April 14, 2024 Category: Hematology Authors: Yizhou Peng Jinjin Huang Jin Yin Fankai Meng Yang Cao Liang Huang Dengju Li Yicheng Zhang Donghua Zhang Li Meng Zhiqiang Han Zhenya Hong Source Type: research
Frontline combination of dasatinib and low-intensity chemotherapy in adults with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia
CONCLUSIONS: Our results suggest that dasatinib-based low-intensity chemotherapy is safe and effective as an induction strategy in the Chinese population. Allo-HSCT plays a crucial role in the long-term outcomes of patients with Ph+ ALL.CLINICAL TRIAL REGISTRATION: The trial was registered at ClinicalTrials.gov as NCT02690922.PMID:38616308 | DOI:10.1080/17474086.2024.2343885 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - April 14, 2024 Category: Hematology Authors: Yizhou Peng Jinjin Huang Jin Yin Fankai Meng Yang Cao Liang Huang Dengju Li Yicheng Zhang Donghua Zhang Li Meng Zhiqiang Han Zhenya Hong Source Type: research
Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Bone Marrow Transplantation, Published online: 13 April 2024; doi:10.1038/s41409-024-02284-5Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - April 13, 2024 Category: Hematology Authors: Arnon Nagler Myriam Labopin Ryszard Swoboda Thomas Schroeder Rose-Marie Hamladji Laimonas Griskevicius Urpu Salmenniemi Alessandro Rambaldi Stephan Mielke Alexander Kulagin Jakob Passweg Thomas Luft Tobias Gedde-Dahl Edouard Forcade Grzegorz Helbig Matthi Source Type: research
Understanding hemoglobin contribution to high-dose methotrexate disposition —population pharmacokinetics in pediatric patients with hematological malignancies
ConclusionThe developed population pharmacokinetic model can contribute to the therapy optimization during HDMTX in pediatric patients with ALL and NHL. In addition to renal function and body weight, it describes the influence of hemoglobin on CL, allowing better understanding of its contribution to the disposition of HDMTX. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - April 11, 2024 Category: Drugs & Pharmacology Source Type: research
